Literature DB >> 34014654

Remarkable and Unexpected Mechanism for (S)-3-Amino-4-(difluoromethylenyl)cyclohex-1-ene-1-carboxylic Acid as a Selective Inactivator of Human Ornithine Aminotransferase.

Wei Zhu1, Peter F Doubleday2, Arseniy Butrin3, Pathum M Weerawarna1, Rafael D Melani2, Daniel S Catlin3, Timothy A Dwight1, Dali Liu3, Neil L Kelleher1,2, Richard B Silverman1,2,4.   

Abstract

Human ornithine aminotransferase (hOAT) is a pyridoxal 5'-phosphate (PLP)-dependent enzyme that was recently found to play an important role in the metabolic reprogramming of hepatocellular carcinoma (HCC) via the proline and glutamine metabolic pathways. The selective inhibition of hOAT by compound 10 exhibited potent in vivo antitumor activity. Inspired by the discovery of the aminotransferase inactivator (1S,3S)-3-amino-4-(difluoromethylene)cyclopentane-1-carboxylic acid (5), we rationally designed, synthesized, and evaluated a series of six-membered-ring analogs. Among them, 14 was identified as a new selective hOAT inactivator, which demonstrated a potency 22× greater than that of 10. Three different types of protein mass spectrometry approaches and two crystallographic approaches were employed to identify the structure of hOAT-14 and the formation of a remarkable final adduct (32') in the active site. These spectral studies reveal an enzyme complex heretofore not observed in a PLP-dependent enzyme, which has covalent bonds to two nearby residues. Crystal soaking experiments and molecular dynamics simulations were carried out to identify the structure of the active-site intermediate 27' and elucidate the order of the two covalent bonds that formed, leading to 32'. The initial covalent reaction of the activated warhead occurs with *Thr322 from the second subunit, followed by a subsequent nucleophilic attack by the catalytic residue Lys292. The turnover mechanism of 14 by hOAT was supported by a mass spectrometric analysis of metabolites and fluoride ion release experiments. This novel mechanism for hOAT with 14 will contribute to the further rational design of selective inactivators and an understanding of potential inactivation mechanisms by aminotransferases.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34014654      PMCID: PMC8369387          DOI: 10.1021/jacs.1c03572

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   16.383


  56 in total

1.  (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction.

Authors:  Yue Pan; Madina R Gerasimov; Trine Kvist; Petrine Wellendorph; Karsten K Madsen; Elena Pera; Hyunbeom Lee; Arne Schousboe; Mary Chebib; Hans Bräuner-Osborne; Cheryl M Craft; Jonathan D Brodie; Wynne K Schiffer; Stephen L Dewey; Steven R Miller; Richard B Silverman
Journal:  J Med Chem       Date:  2011-12-30       Impact factor: 7.446

2.  Global Metabolic Profiling Identifies a Pivotal Role of Proline and Hydroxyproline Metabolism in Supporting Hypoxic Response in Hepatocellular Carcinoma.

Authors:  Ling Tang; Jun Zeng; Pengyu Geng; Chengnan Fang; Yang Wang; Mingju Sun; Changsong Wang; Jiao Wang; Peiyuan Yin; Chunxiu Hu; Lei Guo; Jane Yu; Peng Gao; Enyou Li; Zhengping Zhuang; Guowang Xu; Yang Liu
Journal:  Clin Cancer Res       Date:  2017-10-30       Impact factor: 12.531

3.  Evolutionary relationships among aminotransferases. Tyrosine aminotransferase, histidinol-phosphate aminotransferase, and aspartate aminotransferase are homologous proteins.

Authors:  P K Mehta; T I Hale; P Christen
Journal:  Eur J Biochem       Date:  1989-12-08

4.  Selective Targeting by a Mechanism-Based Inactivator against Pyridoxal 5'-Phosphate-Dependent Enzymes: Mechanisms of Inactivation and Alternative Turnover.

Authors:  Romila Mascarenhas; Hoang V Le; Kenneth D Clevenger; Helaina J Lehrer; Dagmar Ringe; Neil L Kelleher; Richard B Silverman; Dali Liu
Journal:  Biochemistry       Date:  2017-09-06       Impact factor: 3.162

5.  Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.

Authors:  Zhaobing Ding; Russell E Ericksen; Nathalie Escande-Beillard; Qian Yi Lee; Abigail Loh; Simon Denil; Michael Steckel; Andrea Haegebarth; Timothy Shen Wai Ho; Pierce Chow; Han Chong Toh; Bruno Reversade; Sylvia Gruenewald; Weiping Han
Journal:  J Hepatol       Date:  2019-11-11       Impact factor: 25.083

6.  Ornithine aminotransferase promoted the proliferation and metastasis of non-small cell lung cancer via upregulation of miR-21.

Authors:  Yanfeng Liu; Lei Wu; Kai Li; Fengrui Liu; Li Wang; Dongling Zhang; Jing Zhou; Xuan Ma; Shengyu Wang; Shuanying Yang
Journal:  J Cell Physiol       Date:  2018-12-13       Impact factor: 6.384

Review 7.  Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.

Authors:  Laure de Rosamel; Jean-Frederic Blanc
Journal:  Expert Opin Emerg Drugs       Date:  2017-06-12       Impact factor: 4.191

8.  Crystal structure of human ornithine aminotransferase complexed with the highly specific and potent inhibitor 5-fluoromethylornithine.

Authors:  P Storici; G Capitani; R Müller; T Schirmer; J N Jansonius
Journal:  J Mol Biol       Date:  1999-01-08       Impact factor: 5.469

9.  Higher-energy C-trap dissociation for peptide modification analysis.

Authors:  Jesper V Olsen; Boris Macek; Oliver Lange; Alexander Makarov; Stevan Horning; Matthias Mann
Journal:  Nat Methods       Date:  2007-08-26       Impact factor: 28.547

10.  Design, synthesis, and biological activity of a difluoro-substituted, conformationally rigid vigabatrin analogue as a potent gamma-aminobutyric acid aminotransferase inhibitor.

Authors:  Yue Pan; Jian Qiu; Richard B Silverman
Journal:  J Med Chem       Date:  2003-12-04       Impact factor: 7.446

View more
  3 in total

1.  Rational Design, Synthesis, and Mechanism of (3S,4R)-3-Amino-4-(difluoromethyl)cyclopent-1-ene-1-carboxylic Acid: Employing a Second-Deprotonation Strategy for Selectivity of Human Ornithine Aminotransferase over GABA Aminotransferase.

Authors:  Wei Zhu; Arseniy Butrin; Rafael D Melani; Peter F Doubleday; Glaucio Monteiro Ferreira; Mauricio T Tavares; Thahani S Habeeb Mohammad; Brett A Beaupre; Neil L Kelleher; Graham R Moran; Dali Liu; Richard B Silverman
Journal:  J Am Chem Soc       Date:  2022-03-16       Impact factor: 16.383

2.  Inactivators of Ornithine Aminotransferase for the Treatment of Hepatocellular Carcinoma.

Authors:  Richard B Silverman
Journal:  ACS Med Chem Lett       Date:  2021-12-09       Impact factor: 4.345

3.  Determination of the pH dependence, substrate specificity, and turnovers of alternative substrates for human ornithine aminotransferase.

Authors:  Arseniy Butrin; Anastassiya Butrin; Zdzislaw Wawrzak; Graham R Moran; Dali Liu
Journal:  J Biol Chem       Date:  2022-04-20       Impact factor: 5.486

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.